Topic: Hepatocellular Carcinoma
After Eli Lilly’s Cyramza flopped a liver cancer trial five years ago, the drugmaker’s chances in the field looked slim. That all changed Monday.
In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.